Yidafan (ivonescimab) / Summit Therap, Akesobio  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yidafan (ivonescimab) / Akesobio, Summit Therap
NCT06396065: Phase III Study of AK112 for NSCLC Patients

Recruiting
3
420
Europe, Canada, US
AK112 Injection, Pemetrexed, Carboplatin, Placebo Injection
Summit Therapeutics, Akeso
Non-Squamous Non-small Cell Lung Cancer
12/25
12/25
AK112-303, NCT05499390: AK112 in Advanced Non-Small Cell Lung Cancer

Active, not recruiting
3
398
RoW
AK112, Pembrolizumab
Akeso
Advanced Non-small-cell Lung Cancer
06/24
06/25
AK112-306, NCT05840016: AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Recruiting
3
396
RoW
AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel
Akeso
Advanced Squamous Non Small Cell Lung Cancer
12/24
12/25
HARMONi, NCT05184712: Phase 3 Clinical Study of AK112 for NSCLC Patients

Active, not recruiting
3
322
RoW
Ivonescimab (SMT112 or AK112) Injection, Pemetrexed, Carboplatin, Placebo Injection
Akeso, Akeso
Non-Squamous Non-small Cell Lung Cancer
06/24
11/25
HARMONi-3, NCT05899608: Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients

Recruiting
3
400
Canada, US
Ivonescimab Injection, Pembrolizumab Injection
Summit Therapeutics
Non-Small Cell Lung Cancer
09/27
12/27

Download Options